GSDMD Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the LoVo colorectal adenocarcinoma cell line, with disruption of the GSDMD gene to generate a loss-of-function model. This polyclonal format avoids single-cell cloning bottlenecks and is suitable for studying pyroptosis and inflammasome signaling at the population level.
The LoVo cell line is an epithelial adherent colorectal adenocarcinoma line derived from a metastatic supraclavicular lymph node of a 56-year-old male. It serves as a well-characterized model for colon carcinoma, retaining tumorigenic properties and relevant oncogenic signaling pathways. This host context enables investigation of GSDMD function in colorectal cancer cell biology, particularly regarding cell death and inflammatory responses within the tumor microenvironment.
GSDMD is a pore-forming executor of pyroptosis, cleaved by inflammatory caspases (CASP1, CASP4, CASP5) upon inflammasome activation. The liberated N-terminal domain oligomerizes and inserts into the plasma membrane, creating pores that mediate IL-1?? and IL-18 release, HMGB1 secretion, and LDH leakage, culminating in lytic cell death. GSDMD activation is regulated by upstream inflammasome sensors including NLRP3, AIM2, NLRC4, and Pyrin, and it interacts with ASC and the aforementioned caspases. Disruption of GSDMD abrogates this terminal effector mechanism, allowing dissection of upstream signaling events that drive pyroptosis and cytokine maturation.
In LoVo colorectal adenocarcinoma cells, GSDMD-mediated pyroptosis influences the inflammatory microenvironment and may contribute to immune cell recruitment or tumor-promoting inflammation. This knockout polyclonal population allows researchers to investigate how loss of GSDMD affects tumor cell viability, cytokine profiles, and interactions with stromal and immune components. The model is well-suited for studying the role of inflammasome-driven pyroptosis in cancer progression and for evaluating therapeutic strategies that target this pathway in colorectal cancer.
Typical applications include mechanistic studies of pyroptosis, inflammasome signaling analysis, and anti-inflammatory drug screening. Compatible assays include Western blotting for GSDMD cleavage, LDH release and propidium iodide uptake for pore formation, ELISAs for IL-1?? and IL-18, and caspase activity measurements. These cells also support research into drug resistance and validate GSDMD-targeted therapeutics. For additional information, please contact Ascent Research.
